Neoplastic (malignant) related neuropathy. Drug-induced polyneuropathy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with cancer Patients whose neuropathy is due to chemotherapy with taxane drugs or a history of chemotherapy taxane that is a maximum of two months from completion of chemotherapy last Having symptoms of peripheral neuropathy Neuropathy is based on the diagnosis of a neurologist due to chemotherapy Aged between 18 and 80 years Willingness to collaborate in the study
Exclusion criteria
Exclusion criteria: diabetes Carpal tunnel syndrome Reluctance to stay in study Acute psychological symptoms such as depression (taking medication for it) Unforeseen treatments such as surgery, radiation therapy or immunotherapy that were not previously part of the participant's treatment plan Vitamin B6 deficiency or high (diagnosed by doctor and interview) Any signs of allergy or side effects from the drug Deterioration of the patient renal failure Brain metastasis Previous history of axilla or lumbar or pelvic radiotherapy A history of neuropathy due to other conditions that the person had before starting chemotherapy or getting cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Weeks zero and four. Method of measurement: Visual Analogue Scale.;Tingling. Timepoint: Weeks zero and four. Method of measurement: Visual Analogue Scale.;Symptoms of peripheral neuropathy. Timepoint: Weeks zero and four. Method of measurement: Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT) questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shahid Beheshti University of Medical Sciences